STOCK TITAN

Rubric Capital reveals 7.68% Zymeworks (ZYME) stake via Schedule 13G/A

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Rubric Capital Management and David Rosen report a significant stake in Zymeworks Inc. They beneficially own 5,750,000 shares of Zymeworks common stock, representing 7.68% of the outstanding shares. This ownership is reported as being held in the ordinary course of business and not for the purpose of changing or influencing control of the company.

The percentage is based on 74,836,534 Zymeworks common shares outstanding as of November 4, 2025, as disclosed in the company’s Form 10-Q. Rubric Capital has shared voting and dispositive power over these shares, primarily through Rubric Capital Master Fund LP.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Rubric Capital Management LP
Signature:/s/ Michael Nachmani
Name/Title:Michael Nachmani / Chief Operating Officer
Date:02/13/2026
David Rosen
Signature:/s/ David Rosen
Name/Title:David Rosen / Individually
Date:02/13/2026

FAQ

What ownership stake in Zymeworks Inc. does Rubric Capital report in this Schedule 13G/A?

Rubric Capital Management and David Rosen report beneficial ownership of 5,750,000 Zymeworks Inc. common shares, representing 7.68% of the outstanding class. This makes them a significant shareholder based on the company’s reported 74,836,534 shares outstanding as of November 4, 2025.

Who are the reporting persons in the Zymeworks (ZYME) Schedule 13G/A filing?

The reporting persons are Rubric Capital Management LP and David Rosen. Rubric Capital is the investment adviser to certain funds holding Zymeworks shares, and Rosen is the Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital.

How much voting and dispositive power over Zymeworks (ZYME) shares does Rubric Capital have?

Rubric Capital and David Rosen report shared voting power over 5,750,000 shares and shared dispositive power over 5,750,000 shares, with no sole voting or dispositive power. This means decisions over these shares are made jointly, not individually.

What percentage of Zymeworks (ZYME) does the 5,750,000 shares represent?

The filing states that 5,750,000 Zymeworks common shares represent 7.68% of the class. This percentage is calculated using 74,836,534 shares outstanding as of November 4, 2025, as disclosed in Zymeworks’ Form 10-Q for the quarter ended September 30, 2025.

Is Rubric Capital’s stake in Zymeworks (ZYME) intended to influence control of the company?

The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Zymeworks. They are also not held in connection with any control-related transaction, except as allowed for certain nomination activities.

Which Rubric fund has rights to dividends or sale proceeds from Zymeworks (ZYME) shares?

The filing notes that Rubric Capital Master Fund LP, one of the Rubric Funds, has the right to receive or direct the receipt of dividends or sale proceeds from more than 5% of Zymeworks’ common stock, reflecting its economic interest in the reported position.

What type of reporting persons are identified in the Zymeworks (ZYME) Schedule 13G/A?

Rubric Capital Management LP is identified as an investment adviser (IA), and David Rosen is classified as a holding company/control person (HC). These classifications are standard Schedule 13G categories describing their regulatory and control roles over the reported holdings.
Zymeworks

NASDAQ:ZYME

ZYME Rankings

ZYME Latest News

ZYME Latest SEC Filings

ZYME Stock Data

1.70B
71.82M
0.8%
101.5%
9.09%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIDDLETOWN